Original Article
Measuring Adherence to Hepatitis C Direct-Acting Antiviral Medications: Using the VAS in an HCV Treatment Clinic
Abstract
Objectives: To implement the widespread treatment of hepatitis C virus (HCV), validated self-report measures to assess medication adherence are needed for monitoring patients who are prescribed HCV direct-acting antivirals (DAAs). The Visual Analog Scale (VAS) is an efficient and well-validated tool for measuring adherence to antiretrovirals in human immunodeficiency virus populations. This study compared VAS scores with pill counts and serum levels of HCV RNA in a sample of HCV-infected veterans prescribed DAAs.Methods: Veterans initiating HCV DAAs were offered enrollment in our study. HCV treatment was prescribed in accordance with the standard of care. Follow-up study visits were scheduled every 28 days for a total of 12 weeks. Adherence to DAAs was assessed at weeks 4, 8, and 12 using pill counts and the VAS score. Serum levels of HCV RNA were measured at baseline, week 4 of DAA therapy, and week 12 (Ampliprep/Taqman, lower limit of quantification 43 IU/mL).
Results: Between May 2013 and December 2014, 30 veterans were enrolled. Mean adherence via pill count at weeks 4, 8, and 12 (96.2%, 95.2%, and 98.2%, respectively) was nearly identical to the mean VAS scores (96.2%, 96.0%, and 98.2%, respectively). Wilcoxon signed rank tests demonstrated no differences between each VAS and pill count pair. The VAS score inversely correlated with HCV viral load 4 weeks after DAA initiation (r −0.98) and at 12 weeks of treatment (r −0.97).
Conclusions: The VAS score compared favorably with objective measures of adherence. If future studies confirm our results, then the VAS will provide a simple and reliable method of assessing adherence to HCV DAAs in real-world treatment clinics.
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
2. Rogal SS, McCarthy R, Reid A, et al. Primary care and hepatology provider-perceived barriers to and facilitators of hepatitis C treatment candidacy and adherence. Dig Dis Sci 2017;62:1933-1943.
3. Strehlow AJ, Robertson MJ, Zerger S, et al. Hepatitis C among clients of health care for the homeless primary care clinics. J Health Care Poor Underserved 2012;23:811-833.
4. Department of Health and Human Services. National viral hepatitis action plan 2017-2020. https://www.hhs.gov/sites/default/files/National%20Viral%20Hepatitis%20Action%20Plan%202017-2020.pdf?language=en. Accessed October 20, 2017.
5. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002;36( 5 Suppl 1 ):S3-S20.
6. Weiss JJ, Bräu N, Stivala A, et al. Review article: adherence to medication for chronic hepatitis C-building on the model of human immunodeficiency virus antiretroviral adherence research. Aliment Pharmacol Ther 2009;30:14-27.
7. Petersen T, Townsend K, Gordon LA, et al. High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study. Hepatol Int 2016;10:310-319.
8. Butt AA, Yan P, Shaikh OS, Chung RT, et al. Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES. Liver Int 2016;36:1275-1283.
9. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-47.
10. Evon DM, Golin CE, Bonner JE, et al. Adherence during antiviral treatment regimens for chronic hepatitis C: a qualitative study of patient-reported facilitators and barriers. J Clin Gastroenterol 2015;49:e41-e50.
11. Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immun Defic Syndr 2006;43:S79-S87.
12. Amico KR, Fisher WA, Cornman DH, et al. Visual analog scale of ART adherence: association with 3-day self-report and adherence barriers. J Acquir Immun Defic Syndr 2006;42:455-459.
13. Luma HN, Mbatchou Ngahane BH, Mapoure YN, et al. Cross-sectional assessment of three commonly used measures of adherence to combination antiretroviral therapy in a resource limited setting. Int J STD AIDS 2017;28 69-76.
14. Finitsis DJ, Pellowski JA, Huedo-Medina TB, et al. Visual analogue scale (VAS) measurement of antiretroviral adherence in people living with HIV (PLWH): a meta-analysis. J Behav Med 2016;39:1043-1055.
15. Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS 2002;16:269-277.
16. Giordano TP, Guzman D, Clark R, et al. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials 2004;5:74-79.
17. Department of Veterans Affairs, National Hepatitis C Case Registry. Hepatitis C quality care Measures by station. 2014. http://vaww.hepatitis.va.gov/pdf/Station_Data_Reports_2014/Jackson_586.pdf. Accessed January 21, 2016.
18. Adiwijaya BS, Kieffer TL, Adda N, et al. Quantification of the effect of adherence to clinical outcomes in telaprevir-based regimens. http://www.natap.org/2011/hepDART/hepDART_07.htm. Accessed October 30, 2017.
19. Huson LW. Performance of some correlation coefficients when applied to zero-clustered data. http://digitalcommons.wayne.edu/cgi/viewcontent.cgi?article=1101&context=jmasm. Accessed October 20, 2017.
20. Gordon SC, Lawitz EJ, Bacon BR, et al. Adherence to assigned dosing regimen and sustained virologic response among hepatitis C genotype 1 treatment-naive and peg/ribavirin treatment-failures treated with boceprevir plus pegylated interferon alfa-2b/ribavirin. J Hepatol 2011;54:S173-S174.
21. Vo KP, Vutien P, Akiyama MJ, et al. Poor sustained virological response in a multicenter real-life cohort of chronic hepatitis C patients treated with pegylated interferon and ribavirin plus telaprevir or boceprevir. Dig Dis Sci 2015;60:1045-1051.
22. Younossi ZM, Stepanova M, Henry L, et al. Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens. Medicine (Baltimore) 2016;95:e4151.
23. Wagner G, Chan Osilla K, Garnett J, et al. Patient characteristics associated with HCV treatment adherence, treatment completion, and sustained virologic response in HIV coinfected patients. AIDS Res Treat 2011;2011:903480.
24. Lo Re V 3rd, Amorosa VK, Localio AR, et al. Adherence to hepatitis C virus therapy and early virologic outcomes. Clin Infect Dis 2009;48:186-193.
25. Lo Re V 3rd, Teal V, Localio AR, et al. Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study. Ann Intern Med 2011;155:353-360.
26. Smith SR, Wahed AS, Kelley SS, et al. Assessing the validity of self-reported medication adherence in hepatitis C treatment. Ann Pharmacother 2007;41:1116-1123.
27. Gianotti N, Galli L, Bocchiola B, et al. Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy. HIV Med 2013;14:153-160.
